TORRENT PHARMACEUTICALS (NSE:TORNTPHARM) Price Target Increased by 10.81% to 2,111.00

The average one-year price target for TORRENT PHARMACEUTICALS (NSE:TORNTPHARM) has been revised to 2,111.00 / share. This is an increase of 10.81% from the prior estimate of 1,905.08 dated August 1, 2023.

The price target is an average of many targets provided by analysts. The latest targets range from a low of 1,545.30 to a high of 2,538.90 / share. The average price target represents an increase of 8.82% from the latest reported closing price of 1,939.85 / share.

What is the Fund Sentiment?

There are 106 funds or institutions reporting positions in TORRENT PHARMACEUTICALS. This is a decrease of 1 owner(s) or 0.93% in the last quarter. Average portfolio weight of all funds dedicated to TORNTPHARM is 0.12%, an increase of 11.70%. Total shares owned by institutions decreased in the last three months by 6.37% to 11,042K shares.

What are Other Shareholders Doing?

FEMSX - Fidelity Series Emerging Markets Opportunities Fund holds 1,505K shares representing 0.44% ownership of the company. In it's prior filing, the firm reported owning 1,556K shares, representing a decrease of 3.40%. The firm increased its portfolio allocation in TORNTPHARM by 17.51% over the last quarter.

VEIEX - Vanguard Emerging Markets Stock Index Fund Investor Shares holds 1,351K shares representing 0.40% ownership of the company. No change in the last quarter.

PRIDX - T. Rowe Price International Discovery Fund holds 1,329K shares representing 0.39% ownership of the company. No change in the last quarter.

VGTSX - Vanguard Total International Stock Index Fund Investor Shares holds 1,284K shares representing 0.38% ownership of the company. No change in the last quarter.

IEMG - iShares Core MSCI Emerging Markets ETF holds 962K shares representing 0.28% ownership of the company. No change in the last quarter.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Leave a Comment


No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *